MindScape Retreat publishes original reporting and evidence-based analysis on ibogaine therapy, psychedelic medicine, and clinical neuroscience. Our editorial team works alongside board-certified physicians to translate emerging research into actionable insights for patients, families, and healthcare professionals considering treatment options.
64 articles
Stay informed on ibogaine research & clinical insights
New articles delivered to your inbox. No spam.
Featured Articles
All Articles
Stay Informed
Get Research Updates Delivered
Subscribe to receive the latest ibogaine research, clinical updates, and treatment insights from our team. No spam, only substantive updates when we publish.
Unsubscribe any time. We respect your privacy.
Ready to Begin?
The Research Is Compelling. Your Results Can Be Too.
Speak directly with our clinical team about your situation. A confidential consultation costs nothing and could change everything.
Complete archive
Every article we have published, newest first, 64 in total.
- Is 5-MeO-DMT Legal? The Four Questions Hiding Inside That Search
- Ibogaine and Parkinson's Disease: A Caregiver's Guide to Deciding Whether to Look Further
- Bufo vs Ayahuasca: The Four Differences That Actually Change Your Decision
- The Sleepless Window: What Really Happens in the 48 Hours After Your Ibogaine Dose
- Where to Do DMT Therapy: A Legal and Practical Map for 2026
- Toad Medicine Integration: What the Days and Weeks After a 5-MeO-DMT Session Actually Require
- Bufotenine vs DMT: Three Molecules That Keep Getting Confused (and Why It Matters)
- The 5 Hour DMT Trip Explained: Why Duration Depends on the Molecule, the Method, and the Setting
- Ibogaine Treatment in Colorado: What Residents Need to Know in 2026
- MindScape Opens a VIP Oceanfront Ibogaine Residence in Cozumel
- What Is the Bufo Drug? Meaning, Effects, and What the Toad Actually Has to Do With It
- How to Get a Same-Day Passport for Medical Treatment Abroad (2026 Guide)
- What Is Bufo? Understanding the Sonoran Desert Toad Medicine and 5-MeO-DMT
- DMT in Mexico: Where 5-MeO-DMT Retreats Are Held, What They Cost, and How to Choose Safely
- What Is the Bufo Drug? A Complete Guide to Bufo Alvarius and 5-MeO-DMT
- Ibogaine Retreat: What an Authentic, Physician-Supervised Program Looks Like in 2026
- 5-MeO-DMT Retreat Guide: What to Expect, Cost, and How to Choose a Safe Program in 2026
- Ayahuasca vs Ibogaine: Comparing Two Powerful Plant Medicines for Healing
- Bufo Alvarius and 5-MeO-DMT: What the Toad Medicine Really Is (and How It Compares to Synthetic)
- Ibogaine Side Effects and Cardiac Risks: A Physician's Honest Guide to What You Need to Know Before Treatment
- Ibogaine Treatment for Florida Residents: Why Cozumel Is the Closest Legal Option in 2026
- Ibogaine Cost 2026: Complete Pricing Guide for Treatment Centers
- Ibogaine Treatment for Parkinson's: What the Research Shows in 2026
- Psychedelic Therapy in Mexico: A Comprehensive Guide to Ibogaine Treatment & Recovery
- Ibogaine Legal Status Canada 2026: What You Need to Know
- Ibogaine Treatment Seattle: Why Pacific Northwest Patients Travel to Cozumel for Safe, Physician-Supervised Care
- Kyrsten Sinema's Ibogaine Treatment Led to Veteran Clinical Trial Funding in Arizona
- NYT Publishes Groundbreaking Ibogaine Trauma Story — What It Means for Veterans
- SSRI & Ibogaine: Safety Protocols, Tapering Guidelines & Interaction Risk
- Ibogaine vs Ketamine for Depression: Mechanism, Duration, and Outcome Comparison
- The 90-Day Neuroplasticity Window: Why the First 3 Months After Ibogaine Are Critical
- Integration Therapy After Ibogaine Treatment: Why the First 90 Days Determine Long-Term Recovery
- Texas Just Invested $50 Million in Ibogaine Research — Here's What That Means for the Future of Addiction Treatment
- Tennessee Proposes $5 Million for Ibogaine Research — Veterans Say "No One Should Have to Leave the Country We Serve"
- DMT Shows Rapid Results for Depression in Landmark Clinical Trial — What This Means for Psychedelic Therapy
- A Turning Point for Psychedelic Medicine: Why the 2026 Election Could Change Everything for Ibogaine Access
- Why Progressive Ibogaine Dosing with TA and HCl Changes Everything
- MAPS-Columbia Partnership Signals Rising Standards in Psychedelic Practitioner Training
- Compass Pathways Phase 3 Results Raise Questions on Psychedelic Therapy Approval Standards
- MAPS Releases Psychedelic Policy Guidebook as Election Year Promises Reform Wave
- Oregon Makes History as First State to Legalize Medical Ibogaine — What This Means for Addiction Treatment Access
- Discovering El Cielo: Cozumel's Hidden Starfish Paradise
- UK Bets £20M on Addiction Innovation — Here's Why Ibogaine Should Be Part of That Future
- Ibogaine Treatment in 2026: Medical Mainstream Meets Psychedelic Medicine
- Effexor and Ibogaine: Safety, Tapering, Timeline
- Prozac and Ibogaine: Safety, Tapering, Timeline
- Zoloft and Ibogaine: Safety, Tapering, Timeline
- Lexapro and Ibogaine: Safety, Tapering, Timeline
- Psilocybin Emerges as Leading Psychedelic Candidate for Treatment-Resistant OCD
- New Jersey Becomes First Eastern State to Launch Hospital-Based Psilocybin Pilot Program
- Three More States Join the Ibogaine Research Movement — Tennessee, Maryland, and Vermont Introduce New Bills
- Google Co-Founder Sergey Brin Funds $15M Ibogaine Biotech — But Patent Controversy Follows
- Stanford Study: Veterans See 88% PTSD Reduction After Single Ibogaine Treatment
- Bipartisan Coalition in Aspen Maps Strategy for Ibogaine Access as Traditional Rehab Fails Thousands
- How to Choose an Ibogaine Clinic in Mexico: Safety Checklist & Red Flags
- RFK Jr., Trump Administration Very Anxious to Fast-Track Psychedelic Therapy Access
- Mississippi Senate Committee Advances Ibogaine Clinical Trial Bill: Latest State to Explore Psychedelic Therapy
- Iboga Conservation Crisis: Can Demand for Addiction Treatment Coexist with Rainforest Preservation?
- Utah Advances HB 390: Psychedelic Therapy Research Trial to Launch This Summer
- Sugar Addiction: A Neurobiological Disorder and the Therapeutic Potential of Ibogaine
- Breaking Free from Kratom Addiction: How a 10-Day Ibogaine Treatment Offers Real Recovery
- Exploring Ibogaine’s Potential in Addressing Post-Vaccination Syndrome and Parkinson’s Symptoms
- The Synergistic Power of NAD+ and Ibogaine Therapy at MindScape Retreat
- The Synergistic Power of Ibogaine and 5-MeO-DMT (Bufo Alvarius) in Treating PTSD, Addiction, and TBI